The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab.
Donanemab is one of several drugs in late-stage clinical testing that are aimed at a protein called amyloid beta, which accumulates in sticky plaques in the brain. Targeting this protein has been the dominant approach toward treating Alzheimer’s for decades, but has yielded a long list of failed drugs and unsuccessful studies.
Eli Lilly is a 2022 Tax Incentive awardee. This program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts.